Syntara Limited (UUDA) Price & Analysis

Q: What was Pharmaxis Ltd’s price range in the past 12 months?

Pharmaxis Ltd lowest stock price was €0.01 and its highest was €0.03 in the past 12 months.

Q: What is Pharmaxis Ltd’s market cap?

Pharmaxis Ltd’s market cap is €28.03M.

Q: When is Pharmaxis Ltd’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: Is Pharmaxis Ltd overvalued?

According to Wall Street analysts Pharmaxis Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Pharmaxis Ltd pay dividends?

Pharmaxis Ltd does not currently pay dividends.

Q: What is Pharmaxis Ltd’s EPS estimate?

Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Pharmaxis Ltd have?

Pharmaxis Ltd has 1,964,519,300 shares outstanding.

Q: Which hedge fund is a major shareholder of Pharmaxis Ltd?

Currently, no hedge funds are holding shares in DE:UUDA

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

0 Followers

UUDA Stock Chart & Stats

€0.02

€0.00(0.00%)

At close: Jul 15 4:00 PM EDT

€0.02

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.01 - €0.03

Previous CloseN/A

Volume0.00

Average Volume (3M)966.00

Market Cap

€28.03M

Enterprise Value€21.58

Total Cash (Recent Filing)€13.56M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta<0.01

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,964,519,300

10 Day Avg. Volume2,000

30 Day Avg. Volume966

Financial Highlights & Ratios

PEG Ratio-1.96

Price to Book (P/B)2.06

Price to Sales (P/S)0.00

P/FCF Ratio-3.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€0.07

Price Target Upside226.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low LeverageA debt-free balance sheet reduces interest obligations, refinancing exposure, and pressure from creditors while the company works through losses. This gives management greater flexibility to preserve capital, fund operations, or pursue development without the constraints typically created by material leverage.

Substantial Equity BaseThe sizable equity base provides a meaningful capital cushion relative to the company’s assets and reduces immediate balance-sheet fragility. That buffer can support continued operations through development periods, although its durability depends on controlling losses and avoiding prolonged cash depletion.

Historical Gross ProfitabilityThe historical gross margin indicates that the business has previously generated attractive gross economics when revenue was present. If commercial activity is restored, that recorded margin provides some evidence of potential product-level profitability, although operating costs must still be brought into alignment.

Bears Say

Persistent Net LossesContinued and worsening net losses indicate that the current business is not yet converting its activities into sustainable earnings. Persistent losses reduce retained capital, weaken returns for shareholders, and make future progress increasingly dependent on achieving commercial scale or securing additional funding.

No Recent RevenueThe absence of reported revenue in the two latest fiscal years leaves the company without a demonstrated current revenue engine. This makes earnings highly dependent on future commercialization and creates substantial uncertainty over when operating costs can be supported by recurring business activity.

Sustained Cash BurnMaterially negative operating and free cash flow shows that ongoing activities consume cash rather than replenish it. Even with low debt, prolonged cash burn can erode the equity cushion and increase reliance on balance-sheet liquidity or external funding to maintain operations and pursue growth.

Syntara Limited News

Syntara boosts R&D funding with A$4.7m tax incentive

The latest announcement is out from Syntara Limited ( ($AU:SNT) ). Syntara Limited has secured an A$4.7 million...

22h ago

Syntara Seeks ASX Quotation for 1.5 Million New Shares

Syntara Limited ( ($AU:SNT) ) has issued an announcement. Syntara Limited has lodged an application with the ASX...

7d ago

Syntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline

Syntara Limited ( ($AU:SNT) ) has provided an update. Syntara Limited, an ASX-listed clinical-stage biotechnology company based in...

7d ago

Syntara Loss Widens as Revenue Falls and Asset Base Shrinks

Syntara Limited ( ($AU:SNT) ) has shared an announcement. For the 2026 financial year, Syntara reported a 7.9%...

26d ago

Syntara to Brief Investors on Expanding Clinical Pipeline in Quarterly Webinar

Syntara Limited ( ($AU:SNT) ) has provided an announcement. Syntara Limited will host an investor webinar on 28...

2M ago

Syntara secures FDA backing and funding as key clinical programs advance

Syntara Limited ( ($AU:SNT) ) has provided an announcement. Syntara Limited reported a pivotal June quarter, marked by...

2M ago

Syntara Releases Early Phase 2a Data on SNT-4728 for Sleep Disorder

Syntara Limited ( ($AU:SNT) ) has issued an update. Syntara Limited has released preliminary information on a phase...

3M ago

Syntara reports early Phase 2 evidence of brain inflammation reduction in prodromal Parkinson’s trial

Syntara Limited ( ($AU:SNT) ) has provided an announcement. Syntara Limited has reported preliminary data from a randomised,...

3M ago

Syntara Shares Halted Ahead of Key Parkinson’s Trial Update

Syntara Limited ( ($AU:SNT) ) has shared an announcement. Syntara Limited has requested and been granted a trading...

3M ago

Syntara Issues 1.75 Million Unquoted Performance Rights Under Incentive Scheme

Syntara Limited ( ($AU:SNT) ) has provided an update. Syntara Limited has issued 1,754,015 unquoted performance rights under...

3M ago

UUDA FAQ

What was Pharmaxis Ltd’s price range in the past 12 months?

Pharmaxis Ltd lowest stock price was €0.01 and its highest was €0.03 in the past 12 months.

What is Pharmaxis Ltd’s market cap?

Pharmaxis Ltd’s market cap is €28.03M.

When is Pharmaxis Ltd’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Pharmaxis Ltd’s earnings last quarter?

Currently, no data Available

Is Pharmaxis Ltd overvalued?

According to Wall Street analysts Pharmaxis Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharmaxis Ltd pay dividends?

Pharmaxis Ltd does not currently pay dividends.

What is Pharmaxis Ltd’s EPS estimate?

Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharmaxis Ltd have?

Pharmaxis Ltd has 1,964,519,300 shares outstanding.

What happened to Pharmaxis Ltd’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pharmaxis Ltd?

Currently, no hedge funds are holding shares in DE:UUDA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Syntara Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-10.75%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Pharmaxis Ltd

Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.

Syntara Limited (UUDA) Earnings & Revenues

Historic Earnings Reports

UUDA Stock 12 Month Forecast

Average Price Target

€0.07

▲(226.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","-1":"-€1","-0.5":"-€0.5","0.5":"€0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.09326775,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€0.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.065287425,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.0373071,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.01,0.01640521153846154,0.022810423076923075,0.029215634615384616,0.035620846153846156,0.042026057692307696,0.04843126923076923,0.05483648076923077,0.06124169230769231,0.06764690384615385,0.07405211538461538,0.08045732692307692,0.08686253846153845,{"y":0.09326775,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.01,0.014252878846153845,0.01850575769230769,0.022758636538461538,0.02701151538461538,0.03126439423076923,0.035517273076923074,0.03977015192307692,0.04402303076923077,0.04827590961538461,0.05252878846153846,0.0567816673076923,0.061034546153846146,{"y":0.065287425,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.01,0.012100546153846155,0.014201092307692308,0.01630163846153846,0.018402184615384613,0.020502730769230766,0.022603276923076922,0.02470382307692308,0.02680436923076923,0.028904915384615384,0.031005461538461537,0.03310600769230769,0.03520655384615384,{"y":0.0373071,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.011,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.011,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.012,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.011,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.012,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.011,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.015,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.014,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.01,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.011,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.016,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.01,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.01,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >